CD8A and neoplasm: In a preclinical mouse model, the combination of bispecific molecules targeting CD3/CEA and CD137L/FAP showed synergistic anti-tumor effects and this was accompanied by an increase of more CD8+ T cells in tumor than with a CD3/CEA bispecific molecule only [79].